Ethyl-EPA in Huntington disease
- 26 July 2005
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 65 (2), 286-292
- https://doi.org/10.1212/01.wnl.0000169025.09670.6d
Abstract
Background: Preliminary evidence suggests beneficial effects of pure ethyl-eicosapentaenoate (ethyl-EPA) in Huntington disease (HD). Methods: A total of 135 patients with HD were randomized to enter a multicenter, double-blind, placebo-controlled trial on the efficacy of 2 g/d ethyl-EPA vs placebo. The Unified Huntington's Disease Rating Scale (UHDRS) was used for assessment. The primary end point was outcome at 12 months on the Total Motor Score 4 subscale (TMS-4). Analysis of covariance (ANCOVA) and a χ2 test on response, defined as absence of increase in the TMS-4, were performed. Results: A total of 121 patients completed 12 months, and 83 did so without protocol violations (PP cohort). Intent-to-treat (ITT) analysis revealed no significant difference between ethyl-EPA and placebo for TMS-4. In the PP cohort, ethyl-EPA proved better than placebo on the χ2 test on TMS-4 (p < 0.05), but missed significance on ANCOVA (p = 0.06). Secondary end points (ITT cohort) showed no benefit of ethyl-EPA but a significantly worse outcome in the behavioral severity and frequency compared with placebo. Exploring moderators of the efficacy of ethyl-EPA on TMS-4 showed a significant interaction between treatment and a factor defining patients with high vs low CAG repeats. Reported adverse events were distributed equally between treatment arms. Conclusions: Ethyl-eicosapentaenoate (ethyl-EPA) (purity >95%) had no benefit in the intent-to-treat cohort of patients with Huntington disease, but exploratory analysis revealed that a significantly higher number of patients in the per protocol cohort, treated with ethyl-EPA, showed stable or improved motor function. Further studies of the potential efficacy of ethyl-EPA are warranted.Keywords
This publication has 28 references indexed in Scilit:
- Experimental therapeutics in transgenic mouse models of Huntington's diseaseNature Reviews Neuroscience, 2004
- Apoptotic Changes in the Aged Brain Are Triggered by Interleukin-1β-induced Activation of p38 and Reversed by Treatment with Eicosapentaenoic AcidPublished by Elsevier BV ,2002
- Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutaminesNature Neuroscience, 2002
- Neuroprotective Effect of Eicosapentaenoic Acid in Hippocampus of Rats Exposed to γ-IrradiationPublished by Elsevier BV ,2002
- The Biochemistry of n-3 Polyunsaturated Fatty AcidsPublished by Elsevier BV ,2002
- Huntington's disease: new hope for therapeuticsTrends in Neurosciences, 2001
- Miscellanea. Small-sample degrees of freedom with multiple imputationBiometrika, 1999
- Mutations in the TIGR Gene in Familial Primary Open-Angle Glaucoma in JapanAmerican Journal of Human Genetics, 1997
- A shortened version of the motor section of the unified Huntington's disease rating scaleMovement Disorders, 1997
- A multiple imputation strategy for clinical trials with truncation of patient dataStatistics in Medicine, 1995